Barclays analyst Michael Lonegan maintains Emera (NYSE:EMA) with a Equal-Weight and lowers the pr

Emera TSE: EMA reported second-quarter adjusted earnings of C$212 million, or C$0.69 per share, as t

Emera (NYSE:EMA) reported quarterly earnings of $0.50 per share which missed the analyst consensus e

Emera (NYSE:EMA) reported quarterly earnings of $0.50 per share which missed the analyst consensus e

HALIFAX, Nova Scotia--(BUSINESS WIRE)--Emera Inc. (“Emera”) (TSX/NYSE: EMA) reported 2026 second qua

[url="]PepGen Inc.[/url] (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next g

Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FD

HALIFAX, Nova Scotia--(BUSINESS WIRE)--Emera Inc. (TSX/NYSE: EMA) today announced it has received fi

Neuronata-R retains conditional approval in South Korea PR Newswire SEOUL, South Korea, July 19, 202

HALIFAX, Nova Scotia--(BUSINESS WIRE)--Series J First Preferred Share quarterly dividend in release

[url="]Niagen Bioscience, Inc.[/url] (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide aden

HALIFAX, Nova Scotia--(BUSINESS WIRE)--On July 13, 2026, the Board of Directors of Emera Inc. (TSX/N

HALIFAX, Nova Scotia--(BUSINESS WIRE)--Today Emera (TSX/NYSE: EMA) announced that it will release it

Johnson and Johnson presents new IMAAVYÂ (nipocalimab-aahu) data at European Academy of Neurology (E

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP)

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults w

WuXi Biologics' Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 C

New TALVEYÂ (talquetamab-tgvs) plus DARZALEX FASPROÂ (daratumumab and hyaluronidase-fihj) data demon

WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility PR Newswir

Johnson and Johnson presents new data further reinforcing the role of nipocalimab in lowering the au

Johnson and Johnson late-breaking results show nipocalimab significantly reduced systemic lupus eryt

Barclays analyst Michael Lonegan maintains Emera (NYSE:EMA) with a Equal-Weight and lowers the pr

Emera (NYSE:EMA) reported quarterly earnings of $1.00 per share which beat the analyst consensus est

Emera (NYSE:EMA) reported quarterly earnings of $1.00 per share which beat the analyst consensus est

Wall Street analysts changed outlook on top names. Check analyst ratings page for full view. See wha

Top Wall Street analysts changed outlooks on top stocks. Check out our analyst ratings page for upgr

Barclays analyst Michael Lonegan initiates coverage on Emera (NYSE:EMA) with a Equal-Weight ratin

Emera (NYSE:EMA) reported quarterly earnings of $0.39 per share which missed the analyst consensus e

Emera Incorporated ("Emera" or the "Company") (NYSE:EMA) announced today that it has

Today, November 7, 2025, Emera Inc. ("Emera") (NYSE:EMA) reported financial results for the

CIBC analyst Mark Jarvi downgrades Emera (NYSE:EMA) from Outperformer to Neutral and raises the p

Arena Pharmaceuticals Files European Marketing Authorization Application for Lorcaserin for Weight C

Affymax to Receive $5 Million Milestone Payment for Acceptance of European Marketing Authorization A

Genzyme Announces EMA Accepts Oral Teriflunomide Marketing Application for Treatment of Multiple Scl

Recordati and Nymox Announce the Start of European Phase III Clinical Trial for NX-1207

CHMP Recommends Approval of BYETTA for Use With Basal Insulin

Catalyst Pharmaceutical Partners Granted Orphan Medicinal Product Designation in European Union for

Allos Therapeutics Requests Re-Examination of CHMP Opinion on FOLOTYN in PTCL at the European Medici

Trius Earns $5 Million Milestone Payment From Bayer for Successful Completion of First Phase 3 Trial

Trius Reports Positive Results From First Phase 3 Trial of Tedizolid in Acute Bacterial Skin and Ski

UPDATE: FDA Psychopharmacologic Drugs Advisory Committee Recommends Approval of Alexza's ADASUVE™

Shire Announces Regulatory Filings in US and EU for New Manufacturing Facility; Approval Will Add Su

Vertex Submits Application for Priority Review and Approval of KALYDECO in the U.S. as First Potenti